Optimal Use of Perampanel in Asian Patients with Epilepsy: Expert Opinion

Perampanel is a once-daily, first-in-class AMPA receptor antagonist approved for the treatment of epilepsy and exhibits broad-spectrum efficacy in a range of seizure types when used as both monotherapy and adjunctive therapy. Clinical studies and real-world evidence have demonstrated the advantages...

Descripción completa

Detalles Bibliográficos
Autores principales: Chinvarun, Yotin, Huang, Chin-Wei, Wu, Ye, Lee, Hsiu-Fen, Likasitwattanakul, Surachai, Ding, Jing, Yamamoto, Takamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312314/
https://www.ncbi.nlm.nih.gov/pubmed/34321883
http://dx.doi.org/10.2147/TCRM.S316476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312314/
https://www.ncbi.nlm.nih.gov/pubmed/34321883
http://dx.doi.org/10.2147/TCRM.S316476

Ejemplares similares